[go: up one dir, main page]

AR084754A1 - Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso - Google Patents

Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso

Info

Publication number
AR084754A1
AR084754A1 ARP110105031A ARP110105031A AR084754A1 AR 084754 A1 AR084754 A1 AR 084754A1 AR P110105031 A ARP110105031 A AR P110105031A AR P110105031 A ARP110105031 A AR P110105031A AR 084754 A1 AR084754 A1 AR 084754A1
Authority
AR
Argentina
Prior art keywords
express
stem cells
composition
placental stem
composition according
Prior art date
Application number
ARP110105031A
Other languages
English (en)
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of AR084754A1 publication Critical patent/AR084754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616—Blood, e.g. platelet-rich plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)

Abstract

Reivindicación 1: Una composición caracterizada porque comprende células madre placentarias y plasma rico en plaquetas, en donde la composición es adecuada para la inyección a un individuo, y en donde las células madre placentarias se adhieren al plástico para cultivo celular, son CD34-, CD10+, CD105+ y CD200+ y no son trofoblastos.Reivindicación 2: La composición de acuerdo con la reivindicación 1, caracterizada porque las células madre placentarias no se obtienen del cordón umbilical. Reivindicación 3: La composición de acuerdo con la reivindicación 1, caracterizada porque la composición no comprende un sustituto óseo implantable y no requiere trombina para retener las células madre placentarias en un sitio de inyección de dicha composición al individuo. Reivindicación 4: La composición de acuerdo con la reivindicación 1, caracterizada porque la inyección de dicha composición al individuo da como resultado la localización prolongada de las células madre placentarias en el sitio de inyección, con respecto a la inyección de células madre placentarias no combinadas con plasma rico en plaquetas. Reivindicación 5: La composición de acuerdo con la reivindicación 1, caracterizada porque las células madre placentarias expresan CD200 y no expresan HLA-G; o expresan CD73, CD105 y CD200; o expresan CD200 y OCT-4; o expresan CD73 y CD105 y no expresan HLA-G; o expresan CD73 y CD105 y facilitan la formación de uno o más cuerpos de tipo embrionario en una población de células placentarias que comprenden dicha célula madre cuando la población se cultiva en condiciones que permiten la formación de un cuerpo de tipo embrionario; o expresan OCT-4 y facilitan la formación de uno o más cuerpos de tipo embrionario en una población de células placentarias que comprenden dicha célula madre cuando la población se cultiva en condiciones que permiten la formación de cuerpos de tipo embrionario. Reivindicación 9: La composición de acuerdo con la reivindicación 1, caracterizada porque la relación volumen-volumen entre las células madre placentarias y el plasma rico en plaquetas en la composición es de alrededor de 1:1.
ARP110105031A 2010-12-30 2011-12-29 Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso AR084754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061428721P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
AR084754A1 true AR084754A1 (es) 2013-06-05

Family

ID=45532031

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110105031A AR084754A1 (es) 2010-12-30 2011-12-29 Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso

Country Status (3)

Country Link
US (1) US20120171161A1 (es)
AR (1) AR084754A1 (es)
WO (1) WO2012092458A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
KR101132545B1 (ko) 2001-02-14 2012-04-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
PT2471906T (pt) 2005-12-29 2019-02-06 Celularity Inc Populações de células estaminais da placenta
EP3524253A1 (en) 2007-09-28 2019-08-14 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
ES2426241T3 (es) 2008-08-22 2013-10-22 Anthrogenesis Corporation Métodos y composiciones para el tratamiento de defectos óseos con poblaciones de células placentarias
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
RS55287B1 (sr) 2010-04-07 2017-03-31 Anthrogenesis Corp Angiogeneza korišćenjem matičnih ćelija iz placente
TW201138792A (en) 2010-04-08 2011-11-16 Anthrogenesis Corp Treatment of sarcoidosis using placental stem cells
AU2011279201B2 (en) 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR20150036186A (ko) * 2012-06-27 2015-04-07 러트거즈,더스테이트유니버시티오브뉴저지 유세포 측정법을 이용한 ｒｎａ 측정에 의한 ｔ-세포 활성화에 대한 신속한 검정
AU2013359076A1 (en) * 2012-12-14 2015-07-02 Anthrogenesis Corporation Anoikis resistant placental stem cells and uses thereof
NL2010225C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for preserving, transporting and storing living biological materials.
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
EP2970875B1 (en) 2013-03-15 2020-04-15 F.Hoffmann-La Roche Ag Cell culture compositions with antioxidants and methods for polypeptide production
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
WO2016049485A1 (en) * 2014-09-26 2016-03-31 Anthrogenesis Corporation Treatment of diabetic foot ulcer using placental stem cells
US20170369845A1 (en) * 2014-12-31 2017-12-28 Anthrogenesis Corporation Methods for isolation of platelets
US9173921B1 (en) * 2015-03-23 2015-11-03 Jaehyun Lim Method of promoting hair growth by administration of bFGF
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (ko) * 2015-08-27 2017-05-23 심민보 혈소판 풍부 혈장을 포함하는 감각신경성 난청 또는 이명을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법
TWI676478B (zh) * 2016-05-20 2019-11-11 國璽幹細胞應用技術股份有限公司 一種用以製備治療糖尿病之醫藥組合物及其用途
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
CN111388649B (zh) * 2020-03-19 2023-09-12 杭州三江上御生物科技有限公司 一种富血小板血浆胎盘多肽组合物及其应用
CN112402365B (zh) * 2020-10-26 2023-10-03 山东博森医学工程技术有限公司 一种用于治疗椎间盘退变疾病的prp凝胶负载脐带间充质干细胞组合物
CN115998668A (zh) * 2021-05-24 2023-04-25 禾美生物科技(浙江)有限公司 脐带间充质干细胞活性肽分泌物、制备方法、应用及皮肤微生态调节剂
CN113398246B (zh) * 2021-06-30 2022-09-20 上海市皮肤病医院 eIF3I-PDL1-IRS4轴在制备难治性溃疡药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5830708A (en) 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
DE69635899T2 (de) 1995-11-17 2006-11-23 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt
KR100696407B1 (ko) 1999-04-16 2007-03-19 더블유엠. 마쉬 라이스 유니버시티 폴리(프로필렌 푸마레이트)-디아크릴레이트 마크로머와가교결합된 생분해성 폴리(프로필렌 푸마레이트) 네트워크
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA3046566A1 (en) 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders
KR101132545B1 (ko) 2001-02-14 2012-04-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2856662C (en) 2005-10-13 2017-09-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
PT2471906T (pt) 2005-12-29 2019-02-06 Celularity Inc Populações de células estaminais da placenta
WO2007079185A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007146123A2 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
CN101657206B (zh) 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
WO2010141654A1 (en) * 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
EP3284818B1 (en) * 2010-01-26 2022-03-09 Celularity Inc. Treatment of bone-related cancers using placental stem cells

Also Published As

Publication number Publication date
WO2012092458A3 (en) 2012-08-23
US20120171161A1 (en) 2012-07-05
WO2012092458A2 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
AR084754A1 (es) Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
AR084753A1 (es) Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp)
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
BR112014032074A2 (pt) construções de tecido conjuntivo tridimensionais engendradas e métodos de fabricar as mesmas
CR20110192A (es) Compuestos que expanden las celulas madres hematopoiéticas
PE20110399A1 (es) Tratamiento de la apoplejia utilizando celulas placentarias aisladas
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
AR081166A1 (es) Angiogenesis por el uso de celulas madre placentarias
CA2801009C (en) Native wharton's jelly stem cells and their purification
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
JP2015159895A5 (es)
MX2018002038A (es) Formulaciones clinicas.
EP2520316A3 (en) Thrombin isolated from blood and blood fractions
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
BR112019002584A2 (pt) método para a geração de células do tipo células formadoras de colônia do mesoderma e/ou endoteliais apresentando capacidade de formação de vasos sanguíneos in vivo
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
UY36475A (es) Composiciones y metodos para el uso de insecticida con bacillus sp d747
WO2017015245A8 (en) Methods and compositions for stem cell transplantation
MX377300B (es) Terapia con células madre en patologías endometriales.
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
WO2014186508A8 (en) Human extensively self-renewing erythroblasts (esre)

Legal Events

Date Code Title Description
FB Suspension of granting procedure